Purpose: To report that iopamidol myelography can induce status epilepticus (SE) in patients carrying the diagnosis of symptomatic epilepsy and to estimate the incidence of seizures in patients undergoing iopamidol myelography. Methods: We retrospectively identified all patients with seizures/SE associated with 1350 iopamidol myelographies during the last 5 years at our institution. The impact of cervical versus lumbar myelography was analysed. Results: Induced by iopamidol myelography two non-epileptic patients suffered from first generalised tonic-clonic seizures and a 67-year-old women with symptomatic epilepsy after a remote ischemic stroke developed a generalised tonic-clonic seizure evolving into a dialeptic and right nystagmus SE (i.e. complex focal status) of 5-hour duration. The incidence of seizures in non-epileptic patients was 0.15%. The incidence of seizure induction for lumbar myelography was lower than for myelographies that included the cervical subarachnoid space. Conclusions: Iopamidol myelography (especially if cervical) is associated with a risk of seizures in non-epileptic individuals and can induce SE in patients with epilepsy. Patients should be informed about the risk of seizure induction.
INTRODUCTION
Iopamidol is a nonionic iodinated contrast medium commonly used in myelography. Although epileptic seizures are less frequently induced by iopamidol myelography than by myelography with metrizamide, they are a known complication of iopamidol and should not be underestimated [1] [2] [3] [4] [5] [6] [7] [8] . Epilepsy is a restriction for the use of iopamidol. To the best of our knowledge status epilepticus (SE) has never been described except for one seizure series possibly representing SE 1 . Here we present a case of SE induced by iopamidol myelography and give an incidence estimate for seizures induced by iopamidol myelography.
CASE REPORTS
A 67-year-old women developed a symptomatic focal epilepsy after an ischemic infarction in the left precentral area 5 years ago. She suffered from rare right-sided clonic seizures. The antiepileptic therapy consisted of clobazam 10 mg per day, phenytoin 200 mg per day and levetiracetam 2000 mg per day. She underwent run-up myelography of the cervical spine for compression of the right C6 nerve root caused by a suspected disk prolapse between the cervical vertebrae five and six. At our institution the standard dose consists of 10.2 g iopamidol which was injected at the lumbar level. The patient was positioned head downwards to allow the contrast medium to float from the lumbar to the cervical subarachnoid space. Forty-five minutes after the injection of iopamidol the patient had a generalised tonic-clonic seizure which progressed to a complex-partial status with nystagmus to the right (semiological classification 9 : SE: generalised tonic-clonic seizure → dialeptic status and right nystagmus status). It was her first episode of SE ever. Fig. 1a displays the electroencephalogram (EEG) 25 minutes after the onset of the status and Fig. 1b shows the EEG 120 minutes after the onset of the status. It was not possible to stop the status with 3 mg lorazepam intravenously. Only when additional 5 mg lorazepam and 1200 mg phenytoin were given intravenously the SE was controlled after 5 hours. Additional doses of phenytoin were intravenously administered leading to a phenytoin level of 31.2 mg l −1 , 5 hours after termination of the status. The EEG 18 hours after termination of the status is presented in Fig. 1c . Three hours after the onset of the status, a computed tomography of the head was performed. Iopamidol was present in the vicinity of the infarction (Fig. 2) . Other causes for the development of the status could not be identified. The patient recovered with no sequels and was transferred to neurosurgery for therapy of the disk prolapse.
In the 5-year period between July 1997 and June 2002 we observed two other patients who developed an epileptic seizure induced by iopamidol myelography. Both patients had no known epilepsy. The first was a 35-year-old male who had a generalised tonic-clonic seizure several hours after a lumbar iopamidol myelography. The second was a 40-year-old female who had a cervical myelography because of a stenosis of the spinal canal. During the myelography the patient developed a generalised tonic-clonic seizure. Postictally she was confused for about 36 hours with initial fever.
Between July 1997 and June 2002, 1350 myelographies with iopamidol were carried out. Therefore, the incidence of epileptic seizures induced by iopamidol myelography in patients without epilepsy was 0.15% (2/1350). As 80.1% of our myelographies were lumbar and only 19.9% included a cervical myelography the incidence of seizure induction for lumbar myelography was lower (0.09%) as compared to cervical myelography (0.37%). 
DISCUSSION

Seizure induction in epileptic patients
This report of a SE induced by iopamidol myelography and one reported seizure series possibly representing SE 1 support the restricted use of this contrast medium in epileptic patients. Two additional patients with known epilepsy reported by Levey et al. 4 developed seizures induced by lumbar iopamidol myelography. Therefore, in patients with epilepsy the gain of information by a iopamidol myelography must be For all publications total number of patients, cases of seizures and incidence of seizures were given (if available).
weighed against the risk of inducing seizures or SE. The patient should be informed about the risk of seizure induction.
Seizure induction in non-epileptic patients
In our retrospective series the incidence for seizures induced by iopamidol myelography in non-epileptic patients was 0.15% which is in the range of 0-0.847% described in the literature (Table 1) 3-5, 7, 8, 10 . Additional patients with seizures induced by iopamidol myelography have been reported without incidence estimates 1, 2, 6 . The seizures typically develop within 12 hours after injection of the contrast medium 6 . Interestingly, two non-epileptic patients developed seizures induced by cervical myelography despite antiepileptic prophylaxis with phenytoin 5 or sodium valproate 8 .
Cervical versus lumbar myelography
We found a higher incidence of seizure induction for cervical as compared to lumbar myelography. Including our two cases, 55% (6/11) of the reported seizures were induced by cervical myelography although this type of myelography comprises not more than one-third of all myelographies in most centres including ours 7, 11 . Therefore, cervical myelographies may have a higher risk of seizure induction. The highest incidence of seizure induction by iopamidol was reported in studies investigating patients undergoing cervical myelographies only 8 or including seizures induced by cervical iopamidol myelography 5 . It has already been reported for iopamidol that side effects were more frequent in cervical as compared to lumbar myelographies 11 . Furthermore, it has been shown for metrizamide that EEG effects are more prominent with cervical than with lumbar myelographies 12 . These findings may be related to the different techniques used in cervical and lumbar myelography. During a cervical myelography the contrast medium is injected into the lumbar subarachnoid space and afterwards the patient is positioned head downwards so that the contrast medium floats from the lumbar to the cervical and in part to the cranial subarachnoid space. Alternatively, iopamidol is directly injected into the cervical subarachnoid space.
Once the contrast medium has reached the cranial subarachnoid space, it enters the extracellular space by passive diffusion through the pia mater. There it causes changes in the transmitter metabolism which may result in overexcitability of the neurons 3 .
In lumbar myelography the contrast medium is injected into the lumbar subarachnoid space and no run-up technique is used so that most of the contrast medium remains in the lumbar subarachnoid space where it cannot irritate the cortex.
Alternative contrast media and protective medications
It is well established that metrizamide has a higher risk of seizure induction than iopamidol. However, there is not much information about the risk of seizures induced by other nonionic contrast media. The results of comparative bioessays are often conflicting 13, 14 . In one bioassay the neural tolerance of iodixanol for example has been considered to be at least equal to that of iopamidol 13 . In a different bioessay the acute neurotoxicity of iopamidol has been considered to be lower than that of iodixanol 14 . No cases of epileptic seizures induced by iodixanol myelography were reported either in the literature or to the producer (Amersham Buchler GmbH & Co., Germany). However, iodixanol is only approved for myelography in several countries and has been used less frequently for this indication.
For the time being we recommend to use iopamidol for myelography because its risk of seizure induction is known and low. Nevertheless informed consent should include the risk of seizure induction and benzodiazepines should be at hand.
